Jones Trading Reiterates Hold Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA)‘s stock had its “hold” rating restated by equities researchers at Jones Trading in a note issued to investors on Tuesday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Trading Down 9.5 %

MURA opened at $1.33 on Tuesday. The company’s 50 day moving average is $3.82 and its 200 day moving average is $3.60. The company has a market cap of $22.91 million, a price-to-earnings ratio of -0.15 and a beta of 3.66. Mural Oncology has a 12-month low of $1.30 and a 12-month high of $5.12.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period last year, the firm posted ($3.57) EPS. As a group, analysts predict that Mural Oncology will post -7.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Commerce Bank purchased a new stake in Mural Oncology in the 3rd quarter worth $39,000. FMR LLC boosted its stake in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after acquiring an additional 11,423 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Mural Oncology during the third quarter worth about $340,000. Geode Capital Management LLC raised its stake in Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after purchasing an additional 4,731 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Mural Oncology in the 4th quarter worth approximately $181,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.